Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
Our study suggests that molecular markers can be sensibly combined with clinical guidelines to determine the risk profile of adjuvant breast cancer patients. Compared with the current German best practice (German-S3), combinations of EPclin with the St. Gallen, German-S3 or NCCN guideline and EPclin alone were dominant from the perspective of the German healthcare system. </AbstractSection> Copyright The Author(s) 2015
Year of publication: |
2015
|
---|---|
Authors: | Blank, Patricia ; Filipits, Martin ; Dubsky, Peter ; Gutzwiller, Florian ; Lux, Michael ; Brase, Jan ; Weber, Karsten ; Rudas, Margaretha ; Greil, Richard ; Loibl, Sibylle ; Szucs, Thomas ; Kronenwett, Ralf ; Schwenkglenks, Matthias ; Gnant, Michael |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 33.2015, 2, p. 179-190
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Gutzwiller, Florian, (2012)
-
Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?
Matter-Walstra, Klazien, (2014)
-
Exact Log-Rank Tests for Unequal Follow-Up
Heinze, Georg, (2003)
- More ...